IPP COMPLEX AS MARKER FOR ERLOTINIB TREATMENT Russian patent published in 2016 - IPC G01N33/574 A61K31/517 A61P35/00 

FIELD: medicine.

SUBSTANCE: present group of inventions relates to medicine. Disclosed is method for prediction of reaction of patient suffering non-small cell lung cancer (NSCLC), to treatment with erlotinib hydrochloride, which involves determining ILK gene expression level in sample of patient's tumour, and comparison of ILK gene expression levels with ILK gene expression levels in tumours of patient population, whereon above treatment has not produced favourable clinical effect, and if ILK gene expression level 0.93 times less in patient's tumour sample, then treatment will produce favourable clinical effect on such patient, which does not respond to gefitinib therapy. Disclosed is employing ILK gene for prediction of NSCLC patients response to erlotinib hydrochloride treatment, and use of erlotinib hydrochloride for NSCLC treatment.

EFFECT: presented group of inventions provides effective prediction of patient's response to erlotinib hydrochloride treatment.

4 cl, 7 dwg, 1 ex